1. Schwarz G. Molybdenum cofactor and human disease. Curr Opin Chem Biol. 2016;31:179–87.
2. Atwal PS, Scaglia F. Molybdenum cofactor deficiency. Mol Genet Metab. 2016;117(1):1–4.
3. Origin Biosciences. NULIBRY (fosdenopterin) for injection, for intravenous use: US prescribing information. 2021. https://www.nulibry.com/pdfs/nulibry-prescribing-information.pdf. Accessed 6 Apr 2021.
4. US Food & Drug Administration. FDA approves first treatment for molybdenum cofactor deficiency type A [media release]. Feb 26 2021. https://www.fda.gov.
5. Alexion Pharmaceuticals. Alexion acquires investigational therapy for infants suffering from catastrophic, ultra-rare genetic neurologic disorder [media release]. 11 Feb 2011. http://www.alexionpharma.com.